Parkinson DiseaseNCT06385184
Social & QoL Behaviors in Parkinson's Disease
An observational study of Parkinson Disease, run by Gregory Wallace at 1 site in United States.
Trial summary
Adults with Parkinson's Disease experience an array of challenges and changes in daily living, behaviors, and functioning throughout the progression of their condition. The investigators want to learn more about the effects of Parkinson's Disease on individuals' social behavior and quality of life (QoL) compared to… Read more about this study
- Who is it for?
- Ages 40 years and olderHealthy volunteers can take part
- Conditions the study is for
- Parkinson Disease
- How many people
- 500 participants
- Where
- 1 siteUnited States
- Study dates
- 8 Mar 2024to 31 Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: The study includes both 40+ year old adults with Parkinson's disease and 40+ year old neurotypical adults
Who may be able to join
- Have been diagnosed with Parkinsons Disease by a healthcare professional
- Are at least 40 years old
- Are at least 40 years old
Who cannot join
- Possess a diagnosis of autism or any other developmental disability (e.g., Down syndrome)
- Neurotypical group
- Have been diagnosed with Parkinson's disease by a healthcare professional
- Possess a diagnosis of autism or any other developmental disability (e.g., Down syndrome)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
The George Washington University
Washington D.C., District of Columbia, 20052
Gregory Wallace, PhD, 202-994-8285, ladn@gwu.edu
About this study
Official title: Social Behaviors and Quality of Life in Individuals With Parkinson's Disease
Adults with Parkinson's Disease experience an array of challenges and changes in daily living, behaviors, and functioning throughout the progression of their condition. The investigators want to learn more about the effects of Parkinson's Disease on individuals' social behavior and quality of life (QoL) compared to people of the same age without Parkinson's Disease.
- Conditions
- Parkinson Disease
- Being tested
- No Intervention
- Medical subject headings
- Parkinson Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No InterventionOther
Observational study with no intervention
| Study group | Role | What they receive |
|---|---|---|
| Parkinson's disease | This group includes adults who:
* Have been diagnosed with Parkinsons Disease by a healthcare professional
* Are at least 40 years old and
* Do not possess a diagnosis of autism or any other developmental disability (e.g., Down syndrome) Receives: Other: No Intervention | |
| Neurotypical adults | This group includes adults who:
* Are at least 40 years old
* Do not have a diagnosis of Parkinsons Disease or any form of dementia and
* Do not have a diagnosis of autism or any other developmental disability (e.g., Down syndrome) Receives: Other: No Intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Subjective Quality of Life
satisfaction with different aspects of life, such as health and social relationships
Measured: through study completion, an average of 1 year
Social Behavior
ability to interact with others
Measured: through study completion, an average of 1 year
Activities of Daily Living
ability to complete tasks to be independent
Measured: through study completion, an average of 1 year
Mental Health
depression and anxiety symptoms
Measured: through study completion, an average of 1 year
Cognition
memory and executive function challenges and strengths
Measured: through study completion, an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Apr 2024
- Study start8 Mar 2024
- Primary completion31 Dec 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Parkinson DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Gregory Wallace
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Gregory Wallace, George Washington University
- Investigators
- Gregory Wallace, PhD, Principal investigator, George Washington University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06385184
- Sponsor's protocol ID
- NCR234859
- Status last verified
- Feb 2026
- First submitted
- 18 Apr 2024
- Last updated
- 13 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Currently, there is no plan to share participant data with other researchers.
Study at a glance
From the registry record, last updated by the sponsor on 13 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Social Behaviors and Quality of Life in Individuals With Parkinson's Disease
- ClinicalTrials.gov ID
- NCT06385184
- Acronym / sponsor ID
- NCR234859
- Conditions
- Parkinson Disease
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- Gregory WallaceUniversity, hospital or other
- Study start
- 8 Mar 2024 (actual)
- Primary completion
- 31 Dec 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 25 Apr 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Adults with Parkinson's Disease experience an array of challenges and changes in daily living, behaviors, and functioning throughout the progression of their condition. The investigators want to learn more about the effects of Parkinson's Disease on individuals' social behavior and quality of life (QoL) compared to people of the same age without Parkinson's Disease.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Parkinson's disease | – | Other: No InterventionThis group includes adults who: * Have been diagnosed with Parkinsons Disease by a healthcare professional * Are at least 40 years old and * Do not possess a diagnosis of autism or any other developmental disability (e.g., Down syndrome) |
| Neurotypical adults | – | Other: No InterventionThis group includes adults who: * Are at least 40 years old * Do not have a diagnosis of Parkinsons Disease or any form of dementia and * Do not have a diagnosis of autism or any other developmental disability (e.g., Down syndrome) |
Who may qualify
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The study includes both 40+ year old adults with Parkinson's disease and 40+ year old neurotypical adults
Key inclusion criteria (3 listed)
- Have been diagnosed with Parkinsons Disease by a healthcare professional
- Are at least 40 years old
- Are at least 40 years old
Key exclusion criteria (4 listed)
- Possess a diagnosis of autism or any other developmental disability (e.g., Down syndrome)
- Neurotypical group
- Have been diagnosed with Parkinson's disease by a healthcare professional
- Possess a diagnosis of autism or any other developmental disability (e.g., Down syndrome)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No InterventionObservational study with no intervention | Other | Neurotypical adults, Parkinson's disease |
Primary outcome
Subjective Quality of Life
Time frame: through study completion, an average of 1 year
satisfaction with different aspects of life, such as health and social relationships
Social Behavior
Time frame: through study completion, an average of 1 year
ability to interact with others
Activities of Daily Living
Time frame: through study completion, an average of 1 year
ability to complete tasks to be independent
Mental Health
Time frame: through study completion, an average of 1 year
depression and anxiety symptoms
Cognition
Time frame: through study completion, an average of 1 year
memory and executive function challenges and strengths
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Feb 2026.
- Individual participant dataSharing planned: No. Currently, there is no plan to share participant data with other researchers.
Related trials for Parkinson Disease
Active, not recruitingPhase 3
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
Carcinoma, Renal Cell
Not yet recruiting
The Effects of Ischemic Conditioning in Individuals With Parkinson's Disease
Parkinson Disease
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease
Active, not recruitingPhase 2
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
Carcinoma, Non-Small-Cell Lung
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Gregory Wallace, PhD principal investigator
George Washington University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Parkinson Disease, run by Gregory Wallace at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 13 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Gregory Wallace, PhD (202-994-8285, ladn@gwu.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Subjective Quality of Life (time frame: through study completion, an average of 1 year). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Feb 2026; AzTrials last refreshed its copy on 8 Nov 2026.